Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A M Scott

Showing results (161-170 of 163) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 163 results.
Preparative Biochemistry & Biotechnology|May 11, 2005
Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditionsR Murphy, S Green, G Ritter, et al.
Cancer Research|June 24, 2000
Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumorsA M Scott, D Geleick, M Rubira, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2001
Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trialA M Scott, F T Lee, W Hopkins, et al.
Pageof 17

Showing results (161-170 of 163) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 163 results.
Preparative Biochemistry & Biotechnology|May 11, 2005
Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditionsR Murphy, S Green, G Ritter, et al.
Cancer Research|June 24, 2000
Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumorsA M Scott, D Geleick, M Rubira, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2001
Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trialA M Scott, F T Lee, W Hopkins, et al.
Pageof 17